NCT04599933 - An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1) | Biotech Hunter

Enrollment

309

Participants

Timeline

Start Date

October 18, 2020

Primary Completion Date

February 11, 2022

Study Completion Date

February 19, 2022

Conditions

Presbyopia

Interventions

DRUG

CSF-1

One drop bilaterally twice daily for approximately 2 weeks.

DRUG

Vehicle

One drop bilaterally twice daily for approximately 2 weeks.

Trial Locations (17)

16066

Orasis Investigative Site, Cranberry Township

18702

Orasis Investigative Site, Wilkes-Barre

27909

Orasis Investigative Site, Elizabeth City

30260

Orasis Investigative Site, Morrow

32757

Orasis Investigative Site, Mt. Dora

33901

Orasis Investigative Site, Fort Myers

38119

Orasis Investigative Site, Memphis

40206

Orasis Investigative Site, Louisville

57701

Orasis Investigative Site, Rapid City

63131

Orasis Investigative Site, St Louis

64133

Orasis Investigative Site, Kansas City

66210

Orasis Investigative Site, Overland Park

79902

Orasis Investigative Site, El Paso

85351

Orasis Investigative Site, Sun City

89052

Orasis Investigative Site, Henderson

90013

Orasis Investigative Site, Los Angeles

91204

Orasis Investigative Site, Glendale